Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 106

Aβ Blood Test for Detecting Early Alzheimer’s Disease Pathology

Posted by fidest press agency su sabato, 14 dicembre 2019

C2N Diagnostics today announced that results from a study of the APTUS™-Aβ blood test showed high performance for identifying presence or absence of Alzheimer’s pathology in the brain. The APTUS™-Aβ blood test measures amyloid beta proteins from a single sample of blood. The study showed that this blood test reliably predicts the presence or absence of brain amyloid, an essential and early marker of Alzheimer’s disease. Dr. Tim West, Vice President of Research & Development for C2N Diagnostics reported the results as part of a Late Breaking Session at the 12th Annual CTAD conference, held Friday, December 6, 2019 in San Diego, CA.In the study, C2N applied the APTUS™-Aβ blood test to 415 samples previously collected from individuals enrolled at six different locations across the United States. Despite differences in how each of the sites previously collected and stored the blood samples, as well as how each site defined presence of amyloid in the brain, the results showed that the APTUS™-Aβ blood test yielded an area under the receiver operator curve (ROC-AUC) performance of 0.86. When the APTUS™-Aβ results were combined with age and presence of the ApoE4 gene, a known genetic risk factor for developing Alzheimer’s disease, the overall test performance increased to an AUC of 0.90.

Rispondi

Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di WordPress.com

Stai commentando usando il tuo account WordPress.com. Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

 
%d blogger hanno fatto clic su Mi Piace per questo: